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ABSTRACT
Chronic lung allograft dysfunction (CLAD) is a serious complication after lung 
transplantation and thought to represent chronic rejection. Increased expression 
of Pentraxin 3 (PTX3), an acute phase protein, was associated with worse outcome 
in lung transplant patients. To determine the role of recipient PTX3 in development 
of chronic rejection, we used a minor alloantigen-mismatched murine orthotopic 
single lung transplant model. Male C57BL/10 mice were used as donors. Male PTX3 
knockout (KO) mice and their wild type (WT) littermates on 129/SvEv/C57BL6/J 
background were used as recipients. In KO recipients, 7/13 grafted lungs were 
consolidated without volume recovery on CT scan, while only 2/9 WT mice showed 
similar graft consolidation. For grafts where lung volume could be reliably analyzed 
by CT scan, the lung volume recovery was significantly reduced in KO mice compared 
to WT. Interstitial inflammation, parenchymal fibrosis and bronchiolitis obliterans 
scores were significantly higher in KO mice. Presence of myofibroblasts and lymphoid 
aggregation was significantly enhanced in the grafts of PTX3 KO recipients. Recipient 
PTX3 deficiency enhanced chronic rejection-like lesions by promoting a fibrotic 
process in the airways and lung parenchyma. The underlying mechanisms and 
potential protective role of exogenous PTX3 as a therapy should be further explored.
INTRODUCTION
Chronic lung allograft dysfunction (CLAD), with 
an incidence of approximately 50% at 5 years after 
lung transplantation, is the biggest impediment to long-
term survival [1]. Damage to the airway epithelium 
and remodeling of the small airways with fibrotic 
obliteration and fibrosis of the lung parenchyma are major 
pathological features of CLAD [2]. Chronic rejection, 
through allogeneic immune response-induced lymphatic 
infiltration and lymphoid tissue formation in the lung 
grafts, is considered the most important contributing factor 
[3–6]. Increasing evidence suggests that inflammation 
mediated by innate immune responses during ischemia-
reperfusion in the lung allograft [7, 8] and activation of 
autoimmunity [9] are also involved in the pathogenesis of 
CLAD. For example, primary graft dysfunction (PGD), 
acute lung injury during the first 72 h after lung transplant, 
is associated with the development of CLAD [10–12]. 
Identification of biomarkers of PGD may help to predict, 
and possibly prevent, PGD as well as CLAD. 
Diamond et al. reported that plasma levels of PTX3, 
an acute phase protein, were significantly increased 
after lung transplantation, and were associated with 
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the development of PGD in transplant recipients with 
idiopathic pulmonary fibrosis (IPF), but not in those 
with COPD [13]. The same group also reported that two 
genetic variants of recipient PTX3 are associated with the 
development of PGD, and one of the variants is associated 
with increased PTX3 plasma levels [14]. Changes in 
PTX3 expression have also been reported in kidney 
transplantation whereby PTX3 expression positively 
correlated with the degree of allograft dysfunction and 
acute renal allograft rejection [15]. 
PTX3 is an important inflammatory mediator and a 
critical component of the humoral arm of innate immunity 
[16, 17]. PTX3 is a soluble pattern recognition receptor 
with both immunostimulatory and immunoregulatory 
functions. It orchestrates clearance of pathogens through 
opsonization of damage- and pathogen-associated 
molecular patterns, regulates clearance of apoptotic and 
necrotic cells, and prevents autoimmune pathology [18, 
19]. Elevation of PTX3 levels in the circulation following 
infection or tissue damage appears to predict poor patient 
outcome [19], as seen in patients with sepsis and acute 
lung injury [20–22]. 
On the other hand, it has been shown that 
PTX3 provides protection against specific fungal, 
bacterial or viral pathogens [18, 19]. Following 
allogeneic transplantation, reactivation of latent human 
cytomegalovirus is a major cause of morbidity and 
mortality and predisposes to severe complications, 
including superinfection by Aspergillus species [23]. In a 
murine model of allogeneic bone marrow transplantation, 
PTX3 treatment induced complete resistance to infection 
and reinfection with invasive aspergillosis [24]. PTX3 
was shown to bind cytomegalovirus, and protected mice 
from primary viral infection and reactivation as well 
as Aspergillus superinfection [23]. Genetic deficiency 
of PTX3 in humans impairs the antifungal capacity of 
neutrophils and may contribute to the risk of invasive 
aspergillosis in patients treated with hematopoietic stem-
cell transplantation [25]. 
The function of PTX3 in solid organ transplantation, 
however, has not been studied. In the present study, we 
hypothesized that the endogenous recipient-derived PTX3 
plays an important role in chronic rejection pathogenesis 
and dampens inflammation and fibrosis after lung 
transplantation. We tested our hypothesis using a minor-
mismatched orthotopic lung transplantation model [26] 
with PTX3 knockout (KO) mice and their wild type (WT) 
littermates as recipients. 
RESULTS
PTX3 KO recipients show increased lung graft 
consolidation and reduced lung volume
We set off to perform left lung transplantation on 
WT and KO mice. Three KO recipients died early after 
lung transplantations on days 3 (n = 2) and 10. These mice 
were found up to 16 hours after death and the autopsy did 
not identify a cause of death. Due to this early mortality 
and more lung consolidation (see below), more KO 
mice were transplanted, for a total of 9 WT and 13 KO 
recipients that survived until day 28. 
Micro CT scans were used to monitor the allografts. 
All grafts showed consolidation at day 7 post-transplant 
(Figure 1A). While 7/9 of the WT allografts cleared up by 
day 28 (Figure 1A, first row), 6/13 of the KO allografts 
remained partially (Figure 1A, second row) and 7/13 
completely (Figure 1A, third row) consolidated on day 
28. This radiological appearance correlated with the 
gross appearance of the lungs: explanted lungs from WT 
recipients were soft with larger lung volumes. PTX3-KO 
recipients showed shrunken and injured grafted lungs 
(Figure 1B).
For each CT scan, the allograft was given a grade 
from 1 to 5 to reflect the severity of consolidation. Based 
on this semi-quantitative schema, the KO allografts had 
significantly more severe consolidation that persisted 
until day 28, compared to the WT group where the 
consolidation resolved (Figure 1C). 
For a more quantitative assessment of the CT scans, 
we measured the actual graft volume. Since 2/9 WT grafts 
and 7/13 KO grafts were completely consolidated, could 
not be distinguished from the surrounding soft tissue 
and chest wall, lung volume was quantified only on the 
remaining grafts with computer software. The KO group 
showed a trend towards lower volumes compared to the 
WT group, even though this difference was not statistically 
significant when analyzed using a 2-way ANOVA (Figure 
1D). We then asked the question whether lung volume 
recovery differed between the KO and WT groups, by 
comparing lung volumes to the day 1 baseline. In the WT 
group, lung volumes were significantly lower on day 7 
compared to day 1; however, the volumes recovered from 
days 14 to 28 (Figure 1E). In contrast, in the KO group, 
volumes on days 7, 14, 21, and 28 were all significantly 
lower than day 1 (Figure 1F). Hence, even after the 
exclusion of the most severely affected allografts from 
the KO group, there was still a difference in lung volume 
recovery between the KO and WT groups. 
Increased lung fibrosis and incidence of 
bronchiolitis obliterans in KO mice
Lung allograft histology was assessed 28 days after 
transplant. Acute rejection was graded according to the 
ISHLT guidelines [27]. Both acute rejection scores and 
airway inflammation scores were similar between the 
WT and KO groups (Figure 2). By contrast, parenchymal 
fibrosis, as assessed with Masson Trichrome staining was 
significantly higher in the KO group (Figure 3A, 3B, 
and Supplementary Figure 2). Moreover, the percentage of 
airways affected by BO was significantly higher in the KO 
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group (Figure 3A, 3C). Furthermore, there was a strong 
correlation between the parenchymal fibrosis and airway 
BO (Figure 3D).
To determine whether the increased fibrosis was 
related to increased numbers of myofibroblasts, we 
performed immunofluorescent staining for α-SMA positive 
cells in the grafts. We excluded α-SMA positive smooth 
muscle cells around vessels and airways. Grafts in KO 
mice had more α-SMA positive staining (myofibroblasts) 
than grafts in WT mice (Figure 4). 
Increased lymphoid aggregation in lung grafts of 
KO mice 
Lymphoid infiltration and aggregation has been 
reported to contribute to the development of CLAD [3–
6]. We examined lymphoid aggregates using CD3/B220 
double immunofluorescent staining, and staining intensity 
was analyzed. KO mice had significantly larger lymphoid 
aggregates in the lung grafts than WT mice (Figure 5A, 
5B). T cell (CD3 positive) and B cell (B220 positive) 
staining were also both significantly higher in the lung 
grafts of KO mice than WT mice (Figure 5C and 5D). 
Neutrophils and macrophages were assessed 
in the lungs of mice at day 28 post transplant by 
immunofluorescence staining for myeloperoxidase 
and F4/80, respectively. The total numbers of cells 
identified by DAPI staining were significantly higher in 
the KO group, however, the numbers of neutrophils and 
macrophages were not significantly different between the 
KO and WT groups (Supplementary Figure 3).
Suppression of cytokines in lung grafts of KO 
mice
We assessed cytokines and chemokines in plasma 
collected on day 28, using a multiplex assay. For this 
exploratory analysis, a commercially-available 22-
plex was chosen, as it captured common cytokines and 
chemokines previously shown to be involved in CLAD/
BO pathogenesis. Among 22 cytokines and chemokines 
analyzed, 17 were below the detection limits. No 
Figure 1: Increased consolidation of lung grafts in PTX3 KO mice. (A) Sequential micro-CT scans were performed after lung 
transplantation. Transplanted left lung grafts are indicated with arrows. Almost all recipients show left lung consolidation on Day 7 after 
lung transplantation. Aeration of the graft lung recovered in 7 out of 9 WT recipients (top panel) and in 6 out of 13 KO recipients (middle 
panel), and did not recover in other KO recipients (lower panel). (B) Lung grafts extracted from WT recipients were soft with large lung 
volumes. Inflammation, injury and volume reduction were seen in grafts of KO recipients that showed consolidation on Micro-CT scan 
(lower panel). (C) Allograft consolidation on CT scan was graded from 1 to 5. Grades show significantly higher consolidation in the KO 
group compared to WT (p = 0.01). (D) Micro-CT lung volumes were analyzed in 7 WT and 6 KO mice in which the lung grafts were 
not completely consolidated. There is a trend towards lower volumes in the KO group. (E–F) Graft volume recovery was assessed by 
comparing the volumes at each time point to day 1 values. Volumes were partially recovered in the WT group but not in the KO group. 
*P < 0.05, **P < 0.005.
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significant differences between the two groups were 
seen in terms of IL-10, IL-12, IL-13, IL-17 and MIP-2 
(CXCL2) in the plasma (Figure 6). 
We then analyzed cytokine and chemokine 
levels in the lung graft tissue. There were no significant 
differences in most cytokines analyzed, including IL-1α, 
IL-ß, TNFα, IFN-γ, IL-6, G-CSF, GM-CSF, IL-17 and IL-7 
(Supplementary Figure 4). Similarly, there were no significant 
differences in the CC chemokines (CCL2, CCL3, CCL4, 
and CCL5) (Supplementary Figure 5A) or CXC chemokines 
Figure 2: No difference in acute rejection grades between lung grafts of KO vs. WT mice. (A and C) Low magnification 
H&E images. (B and D) Enlarged images from selected areas. Acute rejection was graded based on ISHLT criteria in n = 9 WT 
recipients and n = 10 KO recipients (lungs from 3 KO recipients had such extensive fibrosis that acute rejection was not gradable). 
(E) No significant difference in acute rejections scores. (F) No significant difference in airway (B-grade) inflammation scores. 
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(CXCL1, CXCL2 and CXCL10) (Supplementary Figure 5B) 
that were examined. Interestingly, however, IL-2, IL-15, 
IL-12, IL-5, IL-9, and IL-10, were significantly reduced in 
KO mice compared to WT mice (Figure 7).
DISCUSSION
In the present study, using PTX3 KO mice, we 
demonstrate that the presence of PTX3 in lung transplant 
recipients plays a protective role against the development 
of chronic rejection-like pathology by reducing fibrotic 
lesions in small airways and lung parenchyma, which 
may be mediated through the inhibition of lymphocyte 
infiltration and aggregation in the lung. 
The mouse lung transplant model for CLAD 
studies
A major challenge to the study of mechanisms of 
development of CLAD is the lack of proper animal models 
[28]. The development of a mouse lung transplant model 
[26, 29] is a significant breakthrough in lung transplant 
research, which allows the use of transgenic mice for 
mechanistic studies. Fan et al., transplanting lungs from 
C57BL/10 H-2(b) mice into C57BL/6 mice, identified BO 
lesions at day 28 after lung transplantation [30]. We have 
recently used this model and demonstrated mixed airway 
and parenchymal lesions reminiscent of the pathological 
changes seen in CLAD [31]. The airway BO lesions appear 
to be a good correlate of airway fibrosis seen in patients 
with bronchiolitis obliterans syndrome [32]. In addition, 
the parenchymal fibrosis is reminiscent of the diffuse lung 
disease seen in patients with restrictive allograft syndrome 
[32]. In the present study, we again used C57BL/10 H-2(b) 
mice as donors, and the recipients were the F2 progeny 
of C57BL/6 and 129/SvEv/C57BL6/J mice. The lesions 
appear to be more severe than when C57BL/6 mice were 
used as recipients [31]. 
Transplantation of lungs from C57BL/10 to 
C57BL/6 mice results in acute rejection and BO in about 
45–55% of cases [30].  Because both strains express the 
same H-2 alleles, the pathology is driven by an immune 
response directed at minor alloantigens. The PTX3-/- 
animals available for our studies were on a mixed 129/
SvEv/C57BL6/J background. We generated F2 hybrids of 
these animals with C57BL/6 mice. Consequently, certain 
Figure 3: Increased parenchymal fibrosis and bronchiolitis obliterans (BO) in the lung grafts of KO mice. (A) Examples of 
histological features of lung grafts imaged at 100X and 400X (two examples for 400X). (B) Semi-quantitative assessment shows increased % 
of parenchymal fibrosis in KO grafts (n = 9) compared to WT (n = 13) (p = 0.035) and (C) increased % of airways affected by BO lesions in KO 
grafts compared to WT (p = 0.031). *P < 0.05. (D) The % of parenchymal fibrosis significantly correlates with the % of airways affected by BO 
(P = 0.0001). 
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major alloantigens were also present in the recipients in 
variable quantities, suggesting there may have been some 
variability in the degree of alloreactivity from recipient 
to recipient.  This may explain some of the pathological 
variability and the severe lesions in histological sections. 
Despite this variation, PTX3 deficiency clearly worsened 
early radiographic appearances of the allograft, day 28 
pathology, and cellular infiltration. 
One limitation of the present study was that we only 
have tissue and plasma samples collected at the end of 28 
days. Studies from earlier time points would be helpful 
for understanding the role of PTX3 in the early stage of 
development of these pathological changes. However, 
mouse lung transplantation is a technically challenging 
protocol requiring extensive training and practice 
[33]. The mouse availability was further challenged 
by the infertility of female PTX3-/- mice [16, 18]; as a 
result, for this initial proof-of-principle study, we used 
only one time point for tissue collection. To partially 
compensate for this limitation, we used Micro-CT to 
follow changes in lung volume and lung appearance 
after transplantation. More than 50% of grafts from KO 
recipients showed consolidation; even the grafts without 
complete consolidation showed significantly less recovery 
of lung volumes. Micro-CT thus provides a means to 
monitor the status of the graft in a longitudinal fashion in 
individual animals. More detailed morphometric analyses 
of micro-CT scan may be of value and are presently 
being investigated. A major histocompatibility complex 
mismatch murine lung transplant model was recently 
developed, with B6D2F1/J (a cross between C57BL/6J 
and DBA/2J) (Haplotype H2b/d) mice as donors and 
DBA/2J (H2d) mice as recipients [34]. Since most of 
clinical lung transplants are major antigen mismatch, 
CLAD-related studies with this kind of models should be 
considered.
Protective role of PTX3 in lung transplant 
recipients
Our results show that PTX3 in recipients is 
protective against development of airway and parenchymal 
fibrosis. As mentioned earlier, plasma PTX3 levels after 
lung transplantation were significantly associated with 
the development of PGD only in IPF patients, but not in 
COPD patients [13]. Similarly to IPF, CLAD is a fibrotic 
Figure 4: Increased myofibroblasts in lung grafts in KO mice (n = 13) compared to WT (n = 9). (A) Immunofluorescent 
staining of α-SMA of lung grafts. Original staining was converted to pseudocolors with computer software. (B) Inset showing an area in 
the KO lung with a matching image of the marker area overlay (with red, yellow, and white overlays for high, medium, and low intensity 
staining). Positive staining around the blood vessels and airways was excluded as vascular and airway smooth muscles. (C) Positive 
staining in the lung parenchyma was quantified and expressed as % of total lung area, showing increased α-SMA staining in KO grafts 
compared to WT (P = 0.0092). *P < 0.05.
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Figure 5: Increased lymphoid aggregates in lung grafts of KO (n = 9) compared to WT (n = 13) mice. (A) Immunofluorescent 
staining of lymphoid aggregates with anti-CD3 (T cells) and anti-B220 (B cells) double staining and counterstained with DAPI for nuclei. 
Insets for both WT and KO lungs are shown. The cellular overlay matching the inset region with high (red), medium (orange), low 
(yellow), or negative (white) staining for B200 (the red channel) is shown. (B) Lymphoid aggregate areas (P < 0.05), (C) CD3 positive cells 
(P = 0.0013), and (D) B220 positive cells (P = 0.035) were increased in KO compared to WT grafts. *P < 0.05.
Figure 6: Cytokine and chemokine plasma levels at Day 28 were assessed using a microbead multiplex assay. Of 22 
cytokines and chemokines, 17 were below detection limits. No significant differences were found in IL-12, IL-13, IL-10, IL-17, or MIP-2 
between WT (n = 9) and KO (n = 13) mice.
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process, suggesting that PTX3 is linked to the fibrosis 
pathway. This is consistent with the clinical studies that 
report a lack of association between expression levels of 
PTX3 in plasma and COPD, which is an inflammatory 
rather than fibrotic process [35–37]. 
The most significant finding of this present study is 
the reduction in features of chronic rejection seen in WT 
recipients, as reflected by less lung tissue consolidation, 
less pulmonary fibrosis, especially occlusive airway 
lesions, and less myofibroblasts in the lung tissues. These 
results are in agreement with previous studies conducted 
with PTX3 deficient mice. For example, a lack of PTX3 
aggravated post-ischemic acute kidney injury, followed by 
tubular atrophy, interstitial fibrosis, and kidney shrinkage, 
while injection of recombinant PTX3 up to 6 h after 
reperfusion prevented renal leukocyte recruitment and post-
ischemic kidney injury [38]. PTX3 treatment accelerated 
recovery of kidney function after acute injury, by reducing 
collagen expression and α-SMA positivity, and inhibiting 
interstitial fibrosis [39]. PTX3 also plays a protective 
role in cardiomyocyte ischemia reperfusion injury with 
PTX3-deficient mice showing exacerbated heart damage, 
associated with a greater no-reflow area, increased 
neutrophil infiltration, decreased number of capillaries, 
and increased number of apoptotic cardiomyocytes [40]. 
PTX3 treatment ameliorated cardiomyocyte apoptosis and 
infiltration of neutrophils and macrophages and improved 
hemodynamic performance [41]. Recent studies suggest 
that PTX3 produced from bone marrow-derived cells plays 
a crucial role in cardiac protection against myocardial 
I/R injury by attenuating infiltration of neutrophils, 
generation of ROS and inflammatory cytokines [42]. These 
mechanisms may help explain the severe fibrotic lesions 
we observed in PTX3 deficient recipients after mouse lung 
transplantation. Exogenous PTX3 should be considered as 
a therapeutic option for CLAD in the future.
PTX3 deficiency mediates lymphocytic 
infiltration
In the PTX3 KO recipients, dramatic lymphoid 
aggregates were seen in the grafts with increased numbers 
of T cells and B cells. Lymphocytic infiltration has been 
considered as a precursor of fibrous obliteration [3]. 
Lymphoid neogenesis has been found in animal models of 
BO [4], as well as in patients with BO or CLAD after lung 
transplantation [5]. The increased lymphoid aggregates 
in grafts of KO mice may be due to increased lymphoid 
infiltration and/or neogenesis of lymphoid tissues, which 
merits further investigation. We did not find differences 
in neutrophil or macrophage lung infiltration between KO 
and WT groups at day 28 post-transplant. The increased 
cellularity in the lung tissue, therefore, is mainly due to 
the lymphocytes. Earlier time points should be assessed 
in the future to further elucidate the mechanisms of PTX3 
protection. 
Figure 7: Reduced cytokine levels in lung grafts of KO (n = 13) compared to WT (n = 9) mice. Cytokines and chemokines 
in the lung graft tissue lysates were analyzed with a multiplex microbead assay. The levels of a group of cytokines were significantly lower 
in the grafts of KO mice: IL-2 (P = 0.002), IL-5 (P = 0.043), IL-12 (P = 0.032), IL-9 (P = 0.016), IL-15 (P = 0.045), IL-10 (P = 0.015). 
*P < 0.05.
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To explore the underlying mechanisms, we 
measured cytokines and chemokines using a broad 
multiplex assay. Circulating cytokines and chemokines 
were not significantly different between PTX3 KO and 
WT recipients. By contrast, in the lung grafts of PTX3 
KO recipients, several cytokine levels were significantly 
lower than that in WT recipients. IL-2, along with IL-9 
and IL-15, are members of one cytokine family, each 
has a four alpha helix bundle molecular structure; they 
share the gamma chain of IL-2 receptor for signaling. 
This family of cytokines functions as a master regulator 
to influence cell fate decisions, both priming for 
differentiation and helping to maintain a differentiated 
state [43]. Interestingly, the levels of IL-12, a cytokine 
that promotes Th1 differentiation, and IL-5 and IL-10, 
both are Th2 cytokines, were also reduced in allografts 
of KO recipinets. These changes appear to be specific, 
because other cytokines and chemokines examined did 
not show significant differences. IL-2 promotes Th1 
differentiation by inducing IL-12Rβ2 and IL-12Rβ1, 
promotes Th2 differentiation by inducing IL-4Rα [43]. 
We speculate that even though T cells and B cells were 
higher in the allografts of KO recipients than that in WT 
animals, these cells may be under differentiated. Clearly, 
further investigation is required to understanding 
the role of PTX3 in transplantation related cytokine 
production and differentiation of lymphocytes in the 
grafts.
In summary, PTX3 produced by lung allograft 
recipients may help regulate allograft repair, preventing 
fibrosis in the airways and lung tissues, and preventing 
lymphoid aggregation in the lung grafts. Ample evidence 
from animal models has shown that exogenous PTX3 
administration ameliorates tissue injury and improves 
organ function. The protective role of endogenous 
PTX3 demonstrated in the present study suggests that 




PTX3-KO mice were generated by breeding ptx3+/− 
heterozygous animals (129/SvEv/C57BL6/J background 
from Dr. M. M. Matzuk, Baylor College of Medicine) 
with C57BL/6 mice to obtain F2 generation ptx3-/- 
homozygous animals [22, 44, 45]. Mice were genotyped 
by PCR with two pairs of primers (Supplementary Table 1) 
designed against murine PTX3 Exon 2 and human HPRT 
contained in the targeting vector (Supplementary Figure 
1A) [46]. Examples of PCR genotyping were shown in 
Supplementary Figure 1B. Male PTX3-KO mice of 8 to 
17 weeks of age and their male WT littermates were used 
as recipients of lung transplants. Male C57BL/10 of 8-13 
weeks of age (Jackson Laboratory, Bar Harbor, ME, USA) 
were maintained on a standard diet and kept in a pathogen-
free environment for at least one week, and then used as 
donors.
Animal procedures: lung transplantation
Mouse orthortopic lung transplantation was 
conducted following the technique previously described 
[26]. All animals received care in compliance with the 
Guide to the Care and Use of Experimental Animals 
formulated by the Canadian Council on Animal Care. The 
Animal Care Committee of the Toronto General Hospital 
Research Institute approved the experimental protocol. 
After lung transplantation, recipient mice were housed in 
a pathogen-free environment and maintained on a standard 
diet without antibiotics and immunosuppressant until 
euthanized at day 28, and lung tissue and blood samples 
were collected. 
Micro-computer tomography
At Day 1, 7, 14, 21, 28 after lung transplantation, 
mice were lightly anesthetized by isoflurane inhalation 
and microcomputer tomography (micro-CT) was taken 
using GE Locus Ultra Micro CT (GE Healthcare, London, 
Canada) with 4 s anatomical scans to cover the whole lung 
[31]. The allograft appearance on CT scan was assigned 
a grade based on the amount of consolidation: 0 = clear, 
1 = minimal consolidation, 2 = mild consolidation, 3 = 
moderate consolidation, 4 = severe consolidation, 5 
= complete consolidation (where the lung cannot be 
distinguished from the surrounding chest wall). The 
images where the outline of the lungs could be reliably 
defined were used for further volumetric analyses. The 
obtained images were analyzed using MicroView 2.2 
software (GE Healthcare) to measure 3D lung volume, 
using the following approach: The outlines of each lung 
were traced from approximately 10 sections, from the 
apex to the basal portion of the lung region. The software 
generated a 3D region of interest by interpolating between 
each manually drawn region of interest, reconstructing a 
3D volume containing the lung. The graft lung volume 
was then calculated by measuring the volume of this 
region of interest [31].
Lung tissue collection & histological staining
The inferior 1/8 of the lung allograft was clamped, 
cut off, snap-frozen in liquid nitrogen, and preserved at -80 
ºC for later protein analysis. To collect the rest of the lung 
tissue, the left atrium was cut, 0.9% saline was injected 
through the pulmonary artery (PA), and both lungs were 
perfused. Then, 4% paraformaldehyde was injected into 
the lung through the intubated trachea at 20 cmH2O. The 
heart and lungs were removed en-bloc and placed in 10% 
formalin, then transferred into 70% ethanol. Each lung 
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graft was cut into 3 parts: upper, middle and lower. These 
sections were then paraffin-embedded, sectioned, and used 
for hematoxylin and eosin (H&E), or Masson Trichrome 
(MT) staining as described previously [31].
All histological assessments were performed in 
a blinded fashion. Acute rejection was graded based on 
ISHLT criteria [47]. Parenchymal fibrosis was graded 
as percent of lung tissue affected by parenchymal 
fibrosis (estimation made based on MT slides). Airway 
bronchiolitis obliterans (BO) was assessed based on high-
power examination of MT slides: all airways and airways 
affected by (BO) were counted within all parts (upper, 
middle, and lower) of each lung sample. The percentage 
of airways affected by BO was then calculated.
Immunofluorescence staining
Paraffin-embedded tissue sections were 
deparaffinized, and antigen retrieval was performed using 
boiling 0.01M citrate buffer (pH 6) for 20 min. Sections 
were blocked with 5% goat serum in Dako serum-free 
blocking reagent for 30 min. For α-smooth muscle actin 
(α-SMA) staining, sections were incubated overnight at 
4ºC with Cy3-conjugated α-SMA antibody (1:400)(Sigma-
Aldrich, Oakville, Ontario, Canada). After washing with 
PBS-0.1% Tween, sections were counterstained with DAPI 
and mounted with Slow Fade mounting medium (Invitrogen, 
Waltham, MA, USA). For CD3/B220 staining, the sections 
were incubated overnight at 4ºC with CD3 antibody 
(1:200)(DAKO, Mississauga, Ontario, Canada) and Biotin 
conjugated B220 antibody (1:250)(BD, Mississauga, 
Ontario, Canada). After washing, sections were incubated 
with goat anti-rabbit IgG Alexa Fluor® 555 and Alexa 
Fluor® 488 streptavidin (Molecular Probes, Eugene, OR) 
at the dilution of 1:400. Antibodies for myeloperoxidase 
(MPO) (1:400) and F4/80 (1:500)(Abcam, Cambridge, 
MA, USA) were used for neutrophil and macrophage 
staining, respectively. Goat anti-rabbit IgG Alexa Fluor® 
555 (Molecular Probes, Eugene, OR, USA) were used as 
the secondary antibody at the dilution of 1:400. Then the 
sections were counterstained with DAPI and mounted.
Quantification of lymphoid aggregates area
For each lung graft, as described above, sections 
from the upper, middle and lower part were stained and 
the whole area of each section was assessed. Slides were 
digitized using a Tissue Scope confocal fluorescence slide 
scanner (Huron Technologies, Waterloo, Ontario, Canada) 
at 0.5 um per pixel resolution. Computer-aided image 
analysis was performed using Definiens Tissue Studio 
software platform (Definiens AG, Munich, Germany). 
The software was first used to segment the entire lung 
into two sub-regions composed of lymphoid aggregate 
areas and bulk lung tissue, based on the presence of 
CD3 and B220 positive cells in lymphoid aggregates. 
Following this, cellular segmentation was performed 
based on the presence of DAPI signal, which was used 
to identify all cells in the lymphoid aggregate and lung 
regions of interest. Thresholds for positive staining were 
set by observation of true positive cells present in the 
lymphoid aggregates, and background lung tissue, with 
three thresholds each set to classify the CD3 and B220 
positive cells as high, middle, low and negative staining. 
High staining indicated robustly positive cells; medium 
staining indicated positive stained cells, and low indicated 
marginal degrees of staining, but not reaching the 
threshold of true positivity. This machine-learning analytic 
technique is more precise than manual cell counting and 
has been described previously [48]. The high and middle 
intensity positive cells were summed up and divided by 
the whole lung cell number in the same area (counter-
stained with DAPI), to calculate a percentage of CD3 and 
B220 positive cells.  
α-SMA positive cell quantification
α-SMA positive cells include vascular and airway 
smooth muscle cells and myofibroblasts. α-SMA positive 
staining was analyzed with Definiens TissueStudio. 
Positive staining around vessels and bronchi were 
excluded from the analysis so as to focus primarily on 
myofibroblasts in the lung tissue itself, not the vascular 
and airway smooth muscles. As with CD3 and B220 
analysis above, the myofibroblast signal was assessed (this 
time on a per-pixel basis) by thresholding to identify high, 
medium, low and negative signal. The staining intensity of 
positive areas was assessed by counting regions positive 
for each class of signal, shown in screenshots with red 
representing very high, yellow high and white medium 
intensity. These three intensity signals were included as 
positive staining: α-SMA positive pixel count (mm2) /total 
lung area (mm2) X 100%.
Quantification of macrophages and neutrophils 
Six samples each from KO and WT groups 
were available for quantification of macrophages and 
neutrophils. Six fields per mouse were randomly chosen 
and each of the fields consisted of 3 x 3 stitched fields 
captured at 200x magnification on a confocal microscope. 
Number of MPO and F4/80 positive cells and DAPI-stained 
nuclei were counted using ImageJ ver. 1.45r (National 
Institutes of Health, Bethesda, MD, USA). The average 
number of cells per high-power-field was quantified.
Soluble protein measurement: 
Blood was collected at the time of necropsy from 
the inferior vena cava and placed in heparinized tubes 
and centrifuged for 10 min. The plasma was stored at 
–80ºC until further analysis. Cytokines and chemokines 
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in the plasma and in graft lung tissue at day 28 after 
lung transplantation were measured using the Millipore 
Mouse Cytokine/Chemokine Magnetic Bead Panel (BD 
Bioscience, Mississauga, Ontario, Canada). 
Statistical analysis
Data are expressed as mean ± SEM. Binary 
comparisons were made using unpaired two-tailed non-
parametric Mann-Whitney test. Comparison of longitudinal 
microCT data was first analyzed using a two-way analysis 
of variance test. Comparisons between multiple time points 
within the same group were further made using a one-
way analysis of variance, with post hoc comparison using 
Bonferroni correction. Statistical analyses were performed 
using Prism (Graph Pad Software, La Jolla, CA). 
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